ArticleACS chemical neuroscience2018
Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma.
Article in ACS chemical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Meta-analysis and open-source database for in vivo brain Magnetic Resonance spectroscopy in health and disease.Analytical biochemistry · 2023Pooled it
- A Coupled Multimodal Planar Transmit RF Array for Ultrahigh Field Spine MR Imaging.IEEE transactions on bio-medical engineering · 2026Article
- Fast Hadamard-Encoded 7T Spectroscopic Imaging of Human Brain.Tomography (Ann Arbor, Mich.) · 2025Article
- Advanced imaging techniques and non-invasive biomarkers in pediatric brain tumors: state of the art.Neuroradiology · 2024Review
- Magnetic resonance spectroscopy in MELAS syndrome: correlation with CSF and plasma metabolite levels and change after glutamine supplementation.Neuroradiology · 2024Observational
- Atlas-Based Adaptive Hadamard-Encoded MR Spectroscopic Imaging at 3T.Tomography (Ann Arbor, Mich.) · 2023Article
- Meta-analysis and Open-source Database for In Vivo Brain Magnetic Resonance Spectroscopy in Health and Disease.bioRxiv : the preprint server for biology · 2023Article
- Single-Voxel MR Spectroscopy of Gliomas with s-LASER at 7T.Diagnostics (Basel, Switzerland) · 2023Article
- Evaluation of deep learning models for quality control of MR spectra.Frontiers in neuroscience · 2023Article
- Review
- Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy.Neurologia medico-chirurgica · 2021Article
- Predicting cancer malignancy and proliferation in glioma patients: intra-subject inter-metabolite correlation analyses using MRI and MRSI contrast scans.Quantitative imaging in medicine and surgery · 2021Article
- Advanced magnetic resonance spectroscopic neuroimaging: Experts' consensus recommendations.NMR in biomedicine · 2021Article
- Magnetic resonance spectroscopic imaging in gliomas: clinical diagnosis and radiotherapy planning.BJR open · 2020Review
- Methodological consensus on clinical proton MRS of the brain: Review and recommendations.Magnetic resonance in medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Three-dimensional proton magnetic resonance spectroscopic imaging (MRSI) is a powerful non-invasive tool for characterizing spatial variations in metabolic profiles for patients with glioma. Metabolic parameters obtained using this technique have been shown to predict treatment response, disease progression, and transformation to a more malignant phenotype. The availability of ultra-high-field MR systems has the potential to improve the characterization of metabolites. The purpose of this study was to compare the metabolite profiles acquired with conventional long echo time (TE) MRSI at 3T with those obtained with short TE MRSI at 3T and 7T in patients with glioma. The data acquisition parameters were optimized separately for each echo time and field strength to obtain volumetric coverage within clinically feasible data acquisition times of 5-10 min. While a higher field strength did provide better detection of metabolites with overlapping peaks, spatial coverage was reduced and the use of inversion recovery to reduce lipid precluded the detection of lipid in regions of necrosis. For serial evaluation of large, heterogeneous lesions, the use of 3T short TE MRSI may thus be preferred. Despite the limited number of metabolites that it is able to detect, the use of 3T long TE MRSI gives the best contrast in choline/N-acetyl aspartate between normal appearing brain and tumor and also allows the separate detection of lactate and lipid. It may therefore be preferred for serial evaluation of patients with high-grade glioma and for detection of malignant transformation in patients with low-grade glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.